How to appeal a Cigna adult car-t cell therapy denial
ACA §2719 + ERISA §503 · 180-day window · 30-day decision
To appeal a Cigna adult car-t cell therapy denial, file an internal appeal within 180 days of the date on the denial letter through Cigna's member or provider portal, under ACA §2719 + ERISA §503. Cigna returns standard decisions in 30 days; if it upholds the denial you can request an independent external review within 4 months.
The framework that applies to your appeal
Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.
Cigna-specific note: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.
What Cigna's policy requires for adult car-t cell therapy
Cited policy: Cigna coverage policy — Lisocabtagene Maraleucel (Breyanzi)
FDA-approved indication: r/r LBCL 2L+ primary-refractory or relapse <=12 mo (Jun 2022 TRANSFORM) OR 3L+ (Feb 2021 TRANSCEND) OR r/r CLL/SLL after BTKi + BCL2i (Mar 2024) OR r/r MCL post-BTKi (May 2024) OR r/r FL 3L+ (May 2024). Age >=18. ECOG 0-2. LVEF >=40%, CrCl >=30, AST/ALT <5x ULN, total bili <2.0, ANC >=750, plt >=50K. Administered at FACT-accredited REMS-certified ATC. Bridging + Flu/Cy LD bundled.
How Cigna denies adult car-t cell therapy — and how to counter it
Where Cigna pushes back: 1) 'Auto-HSCT preferred 2L'; 2) MCL/CLL/FL indications deemed 'newly approved/insufficient evidence'; 3) Re-treatment after Yescarta denied; 4) Outpatient administration concern.
Counter-arguments that hold up: TRANSFORM (Kamdar Lancet 2022;399:2294) — Breyanzi vs SOC chemo + auto-HSCT in 2L LBCL with EFS HR 0.36 — basis for FDA Jun 24 2022 2L approval. TRANSCEND-CLL-004 (Siddiqi Lancet 2023) → FDA Mar 14 2024 CLL/SLL. TRANSCEND-NHL-001 MCL cohort (Wang Blood 2024) → FDA May 30 2024 MCL. TRANSCEND-FL (Morschhauser Nat Med 2024) → FDA May 15 2024 FL. All FDA-approved + NCCN-listed; CMS NCD 110.24 covers. Breyanzi label permits outpatient infusion at trained ATCs (lower-grade CRS profile per TRANSCEND). Re-treatment after prior anti-CD19 not excluded per label.
What Cigna typically denies for adult car-t cell therapy
Across Cigna's commercial and Medicare books, denials cluster around a small number of patterns. For adult car-t cell therapy, expect:
- Mental health parity violations
- Step therapy
- Specialty drug prior auth
- OON balance billing disputes
Treatments most often denied in this category
These are the adult car-t cell therapy treatments most often flagged for prior auth, step therapy, or medical necessity review:
- Yescarta
- Kymriah
- Tecartus
- Breyanzi
- Carvykti
- Abecma
How to submit the appeal to Cigna
- Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
- Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Cigna cited in the denial.
- File the appeal through Cigna's portal (members: https://my.cigna.com ; providers: https://cignaforhcp.cigna.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
- If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.
Clinician or prior-auth team handling this on the practice side? See Cigna's prior-authorization criteria by drug: Cigna PA criteria on ApprovalHelp.
Frequently asked questions
How long do I have to appeal a Cigna adult car-t cell therapy denial?
Cigna allows 180 days from the date on the denial letter to file an internal appeal. Standard decisions come back within 30 days; expedited decisions for urgent care typically within 72 hours.
What's the fastest way to submit a Cigna appeal?
Members can submit through the Cigna member portal at https://my.cigna.com. Providers should use the provider portal at https://cignaforhcp.cigna.com. Faxed and mailed appeals are accepted but take longer.
What denials does Cigna most often issue for adult car-t cell therapy?
For adult car-t cell therapy, Cigna most often denies on: 1) 'Auto-HSCT preferred 2L'; 2) MCL/CLL/FL indications deemed 'newly approved/insufficient evidence'; 3) Re-treatment after Yescarta denied; 4) Outpatient administration concern. The strongest counters: TRANSFORM (Kamdar Lancet 2022;399:2294) — Breyanzi vs SOC chemo + auto-HSCT in 2L LBCL with EFS HR 0.36 — basis for FDA Jun 24 2022 2L approval. TRANSCEND-CLL-004 (Siddiqi Lancet 2023) → FDA Mar 14 2024 CLL/SLL. TRANSCEND-NHL-001 MCL cohort (Wang Blood 2024) → FDA May 30 2024 MCL. TRANSCEND-FL (Morschhauser Nat Med 2024) → FDA May 15 2024 FL. All FDA-approved + NCCN-listed; CMS NCD 110.24 covers. Breyanzi label permits outpatient infusion at trained ATCs (lower-grade CRS profile per TRANSCEND). Re-treatment after prior anti-CD19 not excluded per label.
What if Cigna denies the appeal too?
After an internal appeal denial you have the right to an external review by an independent reviewer (IRO) — request it within 4 months of the final internal denial.
Related appeal guides
Start your Adult CAR-T cell therapy appeal
Upload your Cigna denial letter — DenialHelp drafts a physician-ready appeal in five minutes, aligned to ACA §2719 + ERISA §503.
Get started →Contact: hello@denialhelp.com